World-renowned lung cancer researcher
2026 Award Recipient
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
Today #ASCO26🔬Genomic profiling from #NCI_MATCH shows high agreement (90.3%) between blood & tissue samples across 4 common cancers💡✨Plus, detection of ctDNA-only alterations opens new avenues for targeted therapies #CancerResearch #LiquidBiopsy
https://www.asco.org/abstracts-presentations/260930
What a thought-provoking #ClinicalTrials discussion w Dr. Amy Curtis, Upstate Carolina NCORP/@Gibbs @SptbgRegional & Dr. Jeff Berenberg @NCORPHawaiiDOC. Both remarkable @theNCI NCORPS leaders! Grateful for you insights on #TMIST, #TAILORx & other pivotal studies w @thecanceretter
The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight (@Gibbs Cancer Center & Research Institute, @University of Hawaii Cancer Center)
https://cancerletter.com/podcastc/20260529_1/
The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight (@Gibbs Cancer Center & Research Institute, @University of Hawaii Cancer Center)
The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of...
Getting NCI clinical trials to the community has never been an easy task. Has it been getting simpler or more ...
cancerletter.com
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
33
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
